LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Fermé

Secteur Soins de santé

467.89 0.07

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

467.08

Max

470.91

Chiffres clés
By Trading Economics
Revenu	-4.7B -3.6B
Ventes	-40M 2.7B
P/E Moyenne du Secteur	30.09 103.001
BPA	-12.83
Marge bénéficiaire	-135.608
Employés	5,400
EBITDA	263M 1.3B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+9.17 upside

Dividendes
By Dow Jones
Prochains Résultats	4 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	128B
Ouverture précédente	467.82
Clôture précédente	467.89

Sentiment de l'Actualité

By Acuity

50%

94 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

463.41 / 481.19 Support & Résistance

Vertex Pharmaceuticals Inc Graphique

Actualités Associées

1 août 2024, 20:45 UTC

Résultats

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6 mai 2024, 20:37 UTC

Résultats

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10 avr. 2024, 22:48 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10 avr. 2024, 21:40 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10 avr. 2024, 21:24 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 avr. 2024, 20:30 UTC

Actualités

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

1 août 2024, 20:30 UTC

Résultats

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 août 2024, 20:03 UTC

Résultats

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 août 2024, 20:02 UTC

Résultats

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 août 2024, 20:02 UTC

Résultats

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

27 juin 2024, 20:15 UTC

Acquisitions, Fusions, Rachats

Vertex Also Sees About $200M of Transaction-Related Compensation Expense Associated With Acceleration of Unvested Awards Pursuant to Alpine Equity Incentive Plans

27 juin 2024, 20:14 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals Expects to Record About $4.4B One-Time Acquired In-Process R&D Expense Related to May Purchase of Alpine Immune Sciences

6 mai 2024, 21:00 UTC

Résultats

Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD

6 mai 2024, 20:15 UTC

Résultats

Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD

6 mai 2024, 20:03 UTC

Résultats

Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX

6 mai 2024, 20:03 UTC

Résultats

Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX

6 mai 2024, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Net $1.1B >VRTX

6 mai 2024, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX

6 mai 2024, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX

23 avr. 2024, 18:54 UTC

Market Talk

Acquisitions, Fusions, Rachats

Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

11 avr. 2024, 20:18 UTC

Acquisitions, Fusions, Rachats

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD

11 avr. 2024, 16:54 UTC

Market Talk

Acquisitions, Fusions, Rachats

Alpine Deal Seen Giving Vertex New Expertise -- Market Talk

11 avr. 2024, 14:46 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

11 avr. 2024, 13:47 UTC

Actions en Tendance

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

10 avr. 2024, 21:47 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 avr. 2024, 21:09 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10 avr. 2024, 20:46 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10 avr. 2024, 20:15 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10 avr. 2024, 20:04 UTC

Acquisitions, Fusions, Rachats

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

10 avr. 2024, 20:03 UTC

Acquisitions, Fusions, Rachats

Vertex Subsidiary Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX

Comparaison

Variation de prix

Vertex Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

9.17% hausse

Prévisions sur 12 Mois

Moyen 510.9 USD 9.17%

Haut 600 USD

Bas 325 USD

Basé sur 23 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

23 ratings

Achat

Maintien

Vente

Basé sur 23 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

463.41 / 481.19Support & Résistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

94 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.